Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending January 16, 2017. The document serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) and does not contain general business updates or financial results for the company.
Key Financial Metrics
The filing does not provide company-wide financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details a specific share transaction involving a senior executive.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document records a routine acquisition of shares by an executive under a deferred bonus plan.
Transaction Details and Management Commentary
The filing discloses the following transaction details:
- Executive: Ms. C Thomas, SVP, HR.
- Transaction Type: Acquisition of Ordinary Shares following the re-investment of dividends paid on January 12, 2017, under the Deferred Annual Bonus Plan Post-Tax.
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Date: January 12, 2017.
- Exchange: London Stock Exchange (XLON).
- Price: £15.7149 per share.
- Volumes:
- Personal contribution: 35.246 shares.
- Matching shares: 35.446 shares.
- Aggregated volume: 70.692 shares.
Investor Verification Checklist
- Verify the total shareholding of Ms. C Thomas post-transaction in subsequent filings.
- Confirm the terms of the Deferred Annual Bonus Plan Post-Tax to understand the matching share mechanism.
- Note that this filing contains no financial performance data; refer to the most recent Form 20-F or earnings release for company-wide metrics.